Moderna and Merck's mRNA vaccine succeeds in melanoma trial

Moderna and Merck announced on Aug. 19 that their personalized mRNA cancer vaccine, intismeran autogene, met its primary goals in a Phase 3 trial for melanoma, marking the first success of an mRNA cancer vaccine in a late-stage study Source: Ars Technica. The trial involved 1,137 patients with high-risk melanoma (stages IIB–IV) who had their tumors surgically removed. Patients were randomized 2:1 to receive either the vaccine combined with Merck's immunotherapy Keytruda (pembrolizumab) or Keytruda alone. The combination significantly extended recurrence-free survival and distant metastasis-free survival compared with Keytruda alone, according to the companies Source: CNBC. Detailed data have not been released; the companies plan to present findings at an upcoming medical conference Source: Ars Technica.

Market reaction

Investors responded with euphoria. Moderna's stock soared about 177%, while Merck's shares rose more than 12% Source: CNBC. The announcement also triggered a surge in Chinese biotech stocks, as companies like Jiangsu Hengrui Pharmaceuticals and CK Life Sciences pursue similar vaccine programs Source: SCMP.

Expert perspectives

Oncologists called the result "a monumental leap forward" and "a big deal for the field" Source: CNN. However, immunologist Antoni Ribas cautioned that the vaccine's success may be limited to cancers with high mutation burdens, such as melanoma, lung, and bladder cancer, and may not work for colon, prostate, or breast cancer Source: El País.

Challenges ahead

Despite the promise, hurdles remain. Manufacturing personalized vaccines quickly and at reasonable cost is a key challenge Source: SCMP. Additionally, misinformation about mRNA technology, including the false "turbo cancer" narrative, could undermine public confidence Source: CNN. The companies will continue the trial to assess overall survival and plan to discuss regulatory approval in the coming months Source: CNBC.